MWMaegen Wallace

Maegen Wallace

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Maegen Wallace has a total of 96 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Does the Location of the Distal Tibial Epiphyseal Fixation Affect Rod Failure in Children With Osteogenesis Imperfecta?

    by Kinsley Wang, Jacob Callister, Maegen Wallace

    Background: Fassier-Duval (FD) rods are commonly used for tibial stabilization in children with osteogenesis imperfecta (OI). However, failure to telescope remains frequent, and the impact of rod positioning and patient age on outcomes remains poorly defined. Methods: A retrospective review of 452 tibial FD rod placements in 102 pediatric OI patients was performed. Rod position on the anteroposterior (AP) and mediolateral (ML) axes was determined using postoperative radiographs. Failure to telescope was assessed as the primary outcome. Secondary outcome was time to failure. Statistical analysis included chi-squared, linear regression, and multivariable logistic regression. Results: The failure to telescope rate was 39.6%. Lateral placement significantly increased the odds of failure (OR: 2.71; 95% CI: 1.48-5.05; P =0.001), whereas medial placement showed a nonsignificant trend (OR: 1.94; P =0.088). Central positioning was associated with the lowest failure rate, although AP positioning was not a significant predictor on multivariate analysis. Younger age was significantly associated with failure (OR: 0.90; 95% CI: 0.85-0.95; P <0.001). Conclusions: Intermediate rod placement on the AP view significantly reduces the risk of telescoping failure in FD-stabilized tibiae in children with OI. Younger age is a strong predictor of failure, likely due to anatomic challenges. Emphasis on optimal rod placement is warranted to improve outcomes and reduce revision rates. Level of Evidence: Level III, retrospective cohort study.

  • Open Access

    An asymptomatic child with a chronic genetic disease

    by Lana Elcic, Josh Hunt, Parker Brown, Maegen Wallace, Jeremiah Long, Dane Van Tassel

  • Open Access

    What's New in Osteogenesis Imperfecta

    by Maegen Wallace, Bryan Menapace, Christina Herrero, Jeanne M. Franzone


  • Open Access

    Pediatric Scoliosis in Osteogenesis Imperfecta: From Genetic Mechanisms to Therapeutic Strategies

    by Vladislav Muldiiarov, Keely Buesing, Maegen J. Wallace

    Osteogenesis imperfecta (OI) is a hereditary connective tissue disorder characterized by increased bone fragility and a propensity for multiple fractures, often leading to various skeletal deformities. Spinal involvement, particularly the development of scoliosis, is one of the most serious clinical manifestations of OI, significantly impacting patients' quality of life. Scoliosis in OI is characterized by early onset and rapid progression, complicating its treatment and necessitating special attention. This review article consolidates the results of contemporary molecular‐genetic studies on spinal deformities in children with OI and examines the risk factors for their progression. It provides an overview of existing methods for treating scoliotic deformities in OI, including surgical and conservative approaches, and discusses prospects for the implementation of new therapeutic strategies. The aim of the review is to enhance the understanding of the pathogenesis of spinal deformities in OI and to contribute to the development of more effective methods for their diagnosis and treatment.


  • Open Access

    Evaluation of Constipation in Pediatric Patients with Osteogenesis Imperfecta

    by Katie Vanderzwaag, Jay Byrd, Matthew Van Ormer, Kaeli Samson, David Freestone, Members Of The Bbdc, Maegen Wallace

    Background. Osteogenesis imperfecta (OI) is a genetic disorder of connective tissue that often presents with fractures and bone bowing. Constipation is a common symptom in OI and is likley multifactorial. To our knowledge no assessment of the relationship between OI type, OI complications, and constipation has been conducted in this vulnerable patient population. Methods. A retrospective chart and radiographic review was conducted to assess the relationship between constipation and OI type, age, gender, GI symptoms, mobility scores and overall functionality. A total of 98 children with OI were included. Radiographs were analyzed to determine the presence of acetabular protrusio and the degree of fecal loading. Results. Fifty-three female (54%) and 45 male (46%) OI children with a median age of 85.8 months were analyzed. OI types were 30.6% Type I, 30.6% Type III, 27.6% Type IV, and 11.2% other. Constipation was reported in 60%, 26.7%, 11.1%, and 54.5% of children with types III, I, IV, and other, respectively. There was a statistically significant association between the severity of OI and the report of constipation ( P < .001). Participants who reported weakness had a higher percentage of constipation, 55.6% versus 21.1%, ( P = .001). Sixty percent of children with acetabular protrusion reported constipation, while only 27.4% of children without acetabular protrusion reported constipation ( P < .01). Conclusion. Our study demonstrates a potential link between constipation and severity of OI, with weakness as a likely contributing factor. This study also affirmed an association between acetabular protrusion and constipation. Constipation warrants further investigation in OI as to cause and treatment.

  • Special Collection on Rare Musculoskeletal Diseases 2024

    by Eva S Liu, Maegen J Wallace

  • Open Access

    Genotype–phenotype correlations in 294 pediatric patients with osteogenesis imperfecta

    by Jay J Byrd, Andrew C White, Claire G Nissen, Makayla Schissel, Matthew Van Ormer, Danita Velasco, Maegen Wallace

    Osteogenesis imperfecta (OI) is an inherited disorder characterized by bone fragility with extraskeletal manifestations mostly due to COL1A1 and COL1A2 variants. Currently, 23 genes have been implicated in the pathogenesis of OI; however, literature on genotype–phenotype correlation and incidence of non-skeletal clinical features are limited. This study aims to identify genotype–phenotype correlations in patients with OI, allowing clinicians to better inform families of prognosis, optimize patient care, and facilitate evidence-based clinical decision-making. We retrospectively reviewed 294 patients with OI to collect demographic data, clinical characteristics, and genotypic information. Patients were stratified by COL1A1/1A2 vs non-COL1A1/1A2 variants to evaluate differences in phenotype. The majority of OI was due to variants in COL1A1/1A2 (91%), with the remaining 9% due to non-COL1A1/1A2 variants. Most patients in the COL1A1/2 group were White compared to the non-COL1A1/2 group (78% vs 50%; p = 0.004). COL1A/1A2 patients had higher incidence of blue sclerae (83% vs 58%, p = 0.002), dentinogenesis imperfecta (49% vs 15%, p < 0.001), and family history of OI (34% vs 12%, p = 0.03). Those in the non-COL1A1/1A2 group have higher rates of scoliosis compared to those in the COL1A1/1A2 group (62% vs 40%, p = 0.04), as well as higher rates of expressive language disorder/delay (15% vs 0.4% in non-COL1A1/1A2 and COL1A1/1A2 patients, respectively; p < 0.001). Identifying the underlying molecular etiology early is imperative for optimal clinical care, allowing for appropriate risk counseling, identification of affected relatives, and improved anticipatory care and management. These data support that rare subtypes of OI occur more frequently in non-White individuals and demonstrated genetic associations with incidence of blue sclera, dentinogenesis imperfecta, scoliosis, and expressive language disorders.


  • Open Access

    The IFITM5 mutation in osteogenesis imperfecta type V is associated with an ERK/SOX9-dependent osteoprogenitor differentiation defect

    by Ronit Marom, I-Wen Song, Emily C. Busse, Megan E. Washington, Ava S. Berrier, Vittoria C. Rossi, Laura Ortinau, Youngjae Jeong, Ming-Ming Jiang, Brian C. Dawson, et al.

    Osteogenesis imperfecta (OI) type V is the second most common form of OI, distinguished by hyperplastic callus formation and calcification of the interosseous membranes, in addition to the bone fragility. It is caused by a recurrent, dominant pathogenic variant (c.-14C>T) in interferon-induced transmembrane protein 5 ( IFITM5 ). Here, we generated a conditional Rosa26- knockin mouse model to study the mechanistic consequences of the recurrent mutation. Expression of the mutant Ifitm5 in osteo-chondroprogenitor or chondrogenic cells resulted in low bone mass and growth retardation. Mutant limbs showed impaired endochondral ossification, cartilage overgrowth, and abnormal growth plate architecture. The cartilage phenotype correlates with the pathology reported in patients with OI type V. Surprisingly, expression of mutant Ifitm5 in mature osteoblasts caused no obvious skeletal abnormalities. In contrast, earlier expression in osteo-chondroprogenitors was associated with an increase in the skeletal progenitor cell population within the periosteum. Lineage tracing showed that chondrogenic cells expressing the mutant Ifitm5 had decreased differentiation into osteoblastic cells in diaphyseal bone. Moreover, mutant IFITM5 disrupted early skeletal homeostasis in part by activating ERK signaling and downstream SOX9 protein, and inhibition of these pathways partially rescued the phenotype in mutant animals. These data identify the contribution of a signaling defect altering osteo-chondroprogenitor differentiation as a driver in the pathogenesis of OI type V.


  • Open Access

    Assessing the Safety and Efficacy of Tranexamic Acid Usage in Osteogenesis Imperfecta Patients

    by Vincent Bs Eaton, Marco Bs Braaten, Makayla Bs Schissel, Maegen Wallace

    Background: Osteogenesis Imperfecta (OI) usually causes an increased fracture burden and bone deformity, with subsequent operations common. In addition to skeletal manifestations, there is a potential increase in bleeding susceptibility due to the increased frequency of orthopedic procedures, warranting investigation into methods to mitigate this risk. This study aims to evaluate the safety and efficacy of tranexamic acid (TXA) usage to reduce intraoperative blood loss in children with OI. We want to assess the potential benefits, risks, and complications involved with TXA use in this patient population. Methods: TXA-receiving patients (cases) were matched 1:1 with non-TXA-receiving controls on the following criteria: age within 2 years, bone category, and OI Type. Descriptive statistics were used to summarize the data. Fisher Exact Test was performed to compare transfusion status between groups. A Wilcoxon Rank Sum test was performed to assess differences between the groups in days of stay, length of surgery, and estimated blood loss (EBL). All analyses were conducted using SAS version 9.4. PP=0.02), with zero TXA patients requiring a transfusion compared with 20% of the control cases. There is also a significant difference in median EBL (P=0.0004) between groups, with TXA patients having decreased intraoperative EBL (20 vs. 62.5 mL). There was also a difference in median days of postoperative stay between TXA-receiving and non–TXA-receiving patients (P=0.001; 2.6 vs. 4 d). Conclusions: Our study concluded that TXA use in OI patients is associated with lower perioperative transfusions and intraoperative blood loss rates. These results support the standard usage of TXA in these patients to reduce intraoperative blood loss. Level of Evidence: Level III